Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

A federal district court ruled in favor of the Health Resources and Services Administration, but raised questions about ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...